Accugenomics, Inc
Diagnostic Imaging
Why pick this one
Accugenomics develops SNAQ-SEQ internal standards that measure limit of blank and limit of detection for each region in each specimen.
Best for
- NGS assay developers needing per-sample quality control
- ctDNA and liquid biopsy assays detecting low-frequency variants
- MRD assays requiring internal standards across longitudinal samples
- NGS panels measuring SNVs, indels, fusions, or CNVs
- SARS-CoV-2 sequencing assays requiring RNA spike-in controls
- Cell therapy manufacturing workflows requiring adventitious-agent detection
Look elsewhere if
- Patients seeking diagnostic imaging scans
- Customers seeking routine clinical laboratory testing directly from a local provider
- Businesses needing emergency, on-site, or same-day diagnostic services
Specialties
- SNAQ-SEQ internal standards for next-generation sequencing
- ctDNA rare-variant detection controls
- myeloid DNA internal standards for actionable AML variants
- MRD assay internal standards
- SARS-CoV-2 RNA spike-in standards
- NGS controls for SNVs, insertions, deletions, fusions, and CNVs
What makes them different
- Patented and proprietary SNAQ-SEQ technology uses synthetic DNA or RNA internal standards added to each specimen
- SNAQ-SEQ provides limit-of-blank and limit-of-detection measurements for each target region in each specimen
- Standards are compatible with amplicon and capture library preparation methods and Illumina and Ion Torrent sequencers
- Accukit mixtures can cover SNVs, insertions, deletions, fusions, and CNVs
- The company has published research describing technical error-rate and per-variant detection measurements in circulating tumor DNA
- Response time
- rapid adventitious agent detection
Distilled from this business's own website.
Contact & Location
- Address
- 1410 Commonwealth Dr Ste 105, Wilmington, NC 28403-0364
- Phone
- 19103326522
- Website
- https://accugenomics.com
- info@accugenomics.com
Services
- NGS assay quality control
- Custom Accukit internal standard development
- Molecular diagnostic assay performance monitoring
- Liquid biopsy assay control development
- Adventitious-agent detection control development
- RNA sequencing assay quantification